Using a CD16xCD33 bispecific killer cell engager (BiKE) that was originally developed to target the CD33+ clone in AML [100], Gleason et al. showed that, despite the low expression of CD16 in MDS patients, MDS-derived CD16+ NK cells can be triggered ex vivo to effectively lyse the CD33 expressing targets, including allogeneic in vitro-generated MDSCs, overcoming the common suppressive effect of the latter on the NK cells [101]. The gene discussed is CD33; the disease is acute myeloid leukemia.